Inspire Medical Systems’s (NYSE:INSP) Q4: Beats On Revenue
Medical technology company Inspire Medical Systems (NYSE:INSP) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 24.5% year on year to $239.7 million. The company expects the full year’s revenue to be around $947.
Inspire Medical Systems, Inc. (NYSE:INSP) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript February 10, 2025 Inspire Medical Systems, Inc. beats earnings expectations. Reported EPS is $1.15, expectations were $0.74. Operator: Good afternoon. My name is Dilem [ph] and I’ll be your conference operator today.
Inspire Medical Systems (INSP) To Report Earnings Tomorrow: Here Is What To Expect
Medical technology company Inspire Medical Systems (NYSE:INSP) will be reporting results tomorrow after market close. Here’s what you need to know. Inspire Medical Systems beat analysts’ revenue expectations by 2.
A Look At The Fair Value Of Inspire Medical Systems, Inc. (NYSE:INSP)
Key Insights The projected fair value for Inspire Medical Systems is US$209 based on 2 Stage Free Cash Flow to
Stifel Nicolaus Sticks to Its Hold Rating for Inspire Medical Systems (INSP)
In a report released today, Jonathan Block from Stifel Nicolaus maintained a Hold rating on Inspire Medical Systems (INSP – Research Report),
Truist cuts Inspire Medical stock target to $235, retains buy rating
Truist Securities adjusted its price target for Inspire Medical Systems (NYSE:INSP) stock, lowering it from $250.00 to $235.00 while maintaining a Buy rating. The adjustment follows the company's fourth-quarter earnings per share (EPS) beat and a guidance for 2025 that surpassed consensus estimates.
Inspire Medical Systems targets $940M-$955M revenue in 2025 with Inspire V launch
Q4 2024 Management View CEO Tim Herbert highlighted milestones in 2024, including surpassing 90,000 patients treated with Inspire therapy, FDA approval of the Inspire V neurostimulator, and achieving full-body MRI compatibility in the European Union.
Truist Financial Sticks to Their Buy Rating for Inspire Medical Systems (INSP)
In a report released today, Richard Newitter from Truist Financial maintained a Buy rating on Inspire Medical Systems (INSP – Research Report).
ETF Daily News17d
Inspire Medical Systems (NYSE:INSP) Given Overweight Rating at KeyCorp
Shares of NYSE INSP opened at $188.77 on Friday. The company has a 50 day moving average of $189.32 and a 200 day moving average of $186.43. Inspire Medical Systems has a twelve month low of $123. ...
Business Insider26d
RBC Capital Sticks to Their Buy Rating for Inspire Medical Systems (INSP)
However, on January 13, Stifel Nicolaus maintained a Hold rating on Inspire Medical Systems (NYSE: INSP). The company has a one-year high of $257.40 and a one-year low of $123.00. Currently ...
Nasdaq18d
Deep Dive Into Inspire Medical Systems Stock: Analyst Perspectives (8 Ratings)
8 analysts have expressed a variety of opinions on Inspire Medical Systems (NYSE:INSP) over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below summarizes ...
Investing6d
Inspire Medical Systems Inc (INSP)
Inspire Medical Systems (NYSE:INSP) reported Q2 EPS of ($0.53), $0.08 better than the analyst estimate of ($0.61). Revenue for the quarter came in at $91.4 million versus the... Leerink Partners ...
Seeking Alpha16d
INSP Inspire Medical Systems, Inc.
View Inspire Medical Systems, Inc. (INSP) current and estimated P/E ratio data provided by Seeking Alpha.